Aroa Biosurgery

CMS Reforms And International Expansion Will Drive US Healthcare Adoption

AnalystConsensusTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

26 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

AU$0.83

24.4% undervalued

15 Aug

AU$0.63

20.2%

1.6%

Author's Valuation

AU$0.8

24.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 0.57%

AnalystConsensusTarget Fair Value

AU$0.8

24.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

16.56%

Biotech revenue growth rate

13.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

NZ$11.36m

Earnings '28

33.25x

PE Ratio '28

NZ$377.75m

Market Cap '28

NZ$377.75m

Market Cap '28

344.90m

No. shares '28

NZ$1.10

Share Price '28

NZ$1.10 Share Price '28

Discounted to 2025 @ 6.48% p.a.

NZ$0.91

Fair Value '25

NZ$0.91 Fair Value '25

Converted to AUD @ 0.9116 NZD/AUD Exchange Rate

AU$0.83

Fair Value '25

CMS Reforms And International Expansion Will Drive US Healthcare Adoption

Shared on01 May 25Fair value Increased 0.57%

Shared on01 May 25
Fair value Increased 0.57%